Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29992322 | 1.00 | AAK1 (0.48) | AAK1IRAK4GSK3BDYRK1AMAP4K4 | |
| SCHEMBL6502882 | 0.86 | IRAK4 (0.49) | AAK1IRAK4GSK3BDYRK1AMAP4K4 | |
| SCHEMBL5251219 | 0.85 | EGFR (0.57) | AAK1IRAK4GSK3BDYRK1APIK3C3 | |
| SCHEMBL8670718 | 0.84 | FDPS (0.50) | AAK1IRAK4GSK3BDYRK1AMAP4K4 | |
| SCHEMBL7909650 | 0.83 | ATR (0.46) | AAK1IRAK4GSK3BDYRK1AMAP4K4 | |
| SCHEMBL5544966 | 0.82 | CYP17A1 (0.47) | AAK1IRAK4GSK3BDYRK1AMAP4K4 | |
| SCHEMBL17155229 | 0.82 | AAK1 (0.49) | AAK1IRAK4GSK3BDYRK1APIK3C3 | |
| SCHEMBL12127932 | 0.82 | FDPS (0.54) | AAK1GSK3BDYRK1APIK3C3 | |
| SCHEMBL5548970 | 0.81 | ATR (0.48) | AAK1IRAK4GSK3BDYRK1AMAP4K4 | |
| SCHEMBL5251601 | 0.81 | GSK3B (0.46) | AAK1IRAK4GSK3BDYRK1AMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| EP-3828179-A1 | CYANOPYRROLIDINES AS DUB MODULATORS | Mission Therapeutics Limited (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-20200369658-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-11-26 | — | — | US | disclosed |
| US-10774078-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2020-09-15 | — | — | US | disclosed |
| US-20190330202-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10392380-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-20180162852-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED | 2018-06-14 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| WO-2016046530-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774078-B2 | Compounds | UCHL1, UCHL3, UCHL5 | AAK1 3901/4885IRAK4 1964/4885GSK3B 1482/4885 |
| US-20180162852-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | AAK1 3689/4885IRAK4 1887/4885GSK3B 1950/4885 |
| US-10392380-B2 | Compounds | UCHL1, UCHL3, UCHL5 | AAK1 3901/4885IRAK4 1964/4885GSK3B 1482/4885 |
| US-20200369658-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | AAK1 3689/4885IRAK4 1887/4885GSK3B 1950/4885 |
| US-20190330202-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | AAK1 3689/4885IRAK4 1887/4885GSK3B 1950/4885 |
| US-20170247365-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | AAK1 3689/4885IRAK4 1887/4885GSK3B 1950/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | AAK1 3689/4885IRAK4 1887/4885GSK3B 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.